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IMGT®, the international ImMunoGeneTics information system®1, (CNRS and Université
Montpellier 2) is the global reference in immunogenetics and immunoinformatics. By its
creation in 1989, IMGT® marked the advent of immunoinformatics, which emerged at
the interface between immunogenetics and bioinformatics. IMGT® is specialized in the
immunoglobulins (IG) or antibodies, T cell receptors (TR), major histocompatibility (MH),
and proteins of the IgSF and MhSF superfamilies. IMGT® has been built on the IMGT-
ONTOLOGY axioms and concepts, which bridged the gap between genes, sequences, and
three-dimensional (3D) structures.The concepts include the IMGT® standardized keywords
(concepts of identification), IMGT® standardized labels (concepts of description), IMGT®
standardized nomenclature (concepts of classification), IMGT unique numbering, and IMGT
Colliers de Perles (concepts of numerotation). IMGT® comprises seven databases, 15,000
pages of web resources, and 17 tools, and provides a high-quality and integrated system
for the analysis of the genomic and expressed IG andTR repertoire of the adaptive immune
responses.Tools and databases are used in basic, veterinary, and medical research, in clini-
cal applications (mutation analysis in leukemia and lymphoma) and in antibody engineering
and humanization. They include, for example IMGT/V-QUEST and IMGT/JunctionAnalysis
for nucleotide sequence analysis and their high-throughput version IMGT/HighV-QUEST
for next-generation sequencing (500,000 sequences per batch), IMGT/DomainGapAlign for
amino acid sequence analysis of IG andTR variable and constant domains and of MH groove
domains, IMGT/3Dstructure-DB for 3D structures, contact analysis and paratope/epitope
interactions of IG/antigen and TR/peptide-MH complexes and IMGT/mAb-DB interface for
therapeutic antibodies and fusion proteins for immune applications (FPIA).
Keywords: IMGT, immunogenetics, immunoinformatics, IMGT-ONTOLOGY, IMGT Collier de Perles, immunoglobu-
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IMGT®: THE BIRTH OF IMMUNOINFORMATICS
IMGT®, the international ImMunoGeneTics information sys-
tem®1 (1), was created in 1989 by Marie-Paule Lefranc at Montpel-
lier, France (CNRS and Université Montpellier 2). The founding
of IMGT® marked the advent of immunoinformatics, a new sci-
ence, which emerged at the interface between immunogenetics and
bioinformatics. For the first time, immunoglobulin (IG) or anti-
body and T cell receptor (TR) variable (V), diversity (D), joining
(J), and constant (C) genes were officially recognized as “genes”
as well as the conventional genes (2–5). This major breakthrough
allowed genes and data of the complex and highly diversified adap-
tive immune responses to be managed in genomic databases and
tools.
The adaptive immune response was acquired by jawed verte-
brates (or gnathostomata) more than 450 million years ago and is
found in all extant jawed vertebrate species from fishes to humans.
Understanding the basis for adaptive immunity, at the level of cell
populations, individual cells, and molecules, has been a major
1http://www.imgt.org
focus of immunology in the past century (6, 7). The adaptive
immune response is characterized by a remarkable immune speci-
ficity and memory, which are the properties of the B and T cells
owing to an extreme diversity of their antigen receptors. The spe-
cific antigen receptors comprise the immunoglobulins (IG) or
antibodies of the B cells and plasmocytes (2) (Figure 1), and
the T cell receptors (TR) (3) (Figure 2). The IG recognize anti-
gens in their native (unprocessed) form, whereas the TR recognize
processed antigens, which are presented as peptides by the highly
polymorphic major histocompatibility (MH, in humans HLA for
human leukocyte antigens) proteins (Figure 2).
The potential antigen receptor repertoire of each individual is
estimated to comprise about 2× 1012 different IG and TR, and
the limiting factor is only the number of B and T cells that
an organism is genetically programed to produce (2, 3). This
huge diversity results from the complex molecular synthesis of
the IG and TR chains and more particularly of their variable
domains (V-DOMAIN) which, at their N-terminal end, recognize
and bind the antigens (2, 3). The IG and TR synthesis includes
several unique mechanisms that occur at the DNA level: com-
binatorial rearrangements of the V, D, and J genes that code the
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FIGURE 1 | An immunoglobulin (IG) or antibody. In vivo, an IG or antibody
is anchored in the membrane of a B cell as part of a signaling B cell receptor
(BcR=membrane IG+CD79) or, as shown here, is secreted (2). An IG is
made of two identical heavy (H, for IG-HEAVY) chains and two identical light
(L, for IG-LIGHT) chains (2). An IG comprises 12 domains (for example, IgG1,
shown here) or 14 domains (IgM or IgE). The V-DOMAIN of each chain and the
C-DOMAIN, one for each L chain and three for each H chain are highlighted.
The light chain (here, L-KAPPA) is made of a variable domain (V-DOMAIN,
here, V-KAPPA) at the N-terminal end and a constant domain (C-DOMAIN,
here, C-KAPPA) at the C-terminal end. The heavy chain (here, H-GAMMA-1) is
made of a VH (at the N-terminal end) and of three CH (four for H-MU or
H-EPSILON) (Table 1) (2). The structure is that of the antibody b12, an
IgG1-kappa, and so far the only complete human IG crystallized [1hzh from
IMGT/3Dstructure-DB (http://www.imgt.org)].
V-DOMAIN [the V–(D)–J being spliced to the C gene that encodes
the C-REGION in the transcript], exonuclease trimming at the
ends of the V, D, and J genes and random addition of nucleotides
by the terminal deoxynucleotidyl transferase (TdT) that creates
the junctional N-diversity regions, and later during B cell differ-
entiation, for the IG, somatic hypermutations and class or subclass
switch (2, 3).
IMGT® manages the diversity and complexity of the IG and
TR and the polymorphism of the MH of humans and other
vertebrates. IMGT® is also specialized in the other proteins of
the immunoglobulin superfamily (IgSF) and MH superfamily
(MhSF) and related proteins of the immune system (RPI) of
vertebrates and invertebrates (1). IMGT® provides a common
access to standardized data from genome, proteome, genetics,
two-dimensional (2D), and three-dimensional (3D) structures.
IMGT® is the acknowledged high-quality integrated knowledge
resource in immunogenetics for exploring immune functional
genomics. IMGT® comprises seven databases (for sequences,
genes and 3D structures) (9–14), 17 online tools (15–30), and
more than 15,000 pages of web resources [e.g., IMGT Scientific
chart, IMGT Repertoire, IMGT Education>Aide-mémoire (31),
the IMGT Medical page, the IMGT Veterinary page, the IMGT
Biotechnology page, the IMGT Immunoinformatics page] (1).
IMGT® is the global reference in immunogenetics and immunoin-
formatics (32–47). Its standards have been endorsed by the
World Health Organization–International Union of Immuno-
logical Societies (WHO–IUIS) Nomenclature Committee since
1995 (first IMGT® online access at the Ninth International Con-
gress of Immunology, San Francisco, CA, USA) (48, 49) and the
WHO–International Nonproprietary Names (INN) Programme
(50, 51).
The accuracy and the consistency of the IMGT® data are
based on IMGT-ONTOLOGY (52–54), the first, and so far, unique
ontology for immunogenetics and immunoinformatics (8, 52–70).
IMGT-ONTOLOGY manages the immunogenetics knowledge
through diverse facets that rely on seven axioms: IDENTIFICA-
TION, DESCRIPTION, CLASSIFICATION, NUMEROTATION,
LOCALIZATION, ORIENTATION, and OBTENTION (53, 54,
58). The concepts generated from these axioms led to the elabora-
tion of the IMGT® standards that constitute the IMGT Scientific
chart: e.g., IMGT® standardized keywords (IDENTIFICATION)
(59), IMGT® standardized labels (DESCRIPTION) (60), IMGT®
standardized gene and allele nomenclature (CLASSIFICATION)
(61), IMGT unique numbering (8, 62–66), and its standardized
graphical 2D representation or IMGT Colliers de Perles (67–70)
(NUMEROTATION).
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FIGURE 2 | AT cell receptor (TR)/peptide-major histocompatibility 1
(pMH1) complex. A TR (here, TR-alpha_beta) is shown (on top, upside
down) in complex with an MH (here, MH1) presenting a peptide in its
groove. In vivo, a TR is anchored in the membrane of a T cell as part of the
signaling T cell receptor (TcR=TR+CD3). A TR is made of two chains, each
comprising a variable domain (V-DOMAIN) at the N-terminal end and a
constant domain (C-DOMAIN) at the C-terminal end (3). The domains are
V-ALPHA and C-ALPHA for the TR-ALPHA chain, V-BETA and C-BETA for the
TR-BETA chain (Table 2) (3). An MH1 is made of the I-ALPHA chain with two
G-DOMAIN (G-ALPHA1 and G-ALPHA2) and a C-LIKE-DOMAIN (C-LIKE),
non-covalently associated with the B2M (a C-LIKE-DOMAIN) (8). The
TR/pMH1 complex structure is 3qfj from IMGT/3Dstructure-DB
(http://www.imgt.org).
The fundamental information generated from these IMGT-
ONTOLOGY concepts, which led to the IMGT Scientific chart
rules is reviewed. The major IMGT® tools and databases
used for IG and TR repertoire analysis, antibody humaniza-
tion, and IG/Ag and TR/pMH structures are briefly presented:
IMGT/V-QUEST (15–20) for the analysis of rearranged nucleotide
sequence with the results of the integrated IMGT/JunctionAnalysis
(21, 22), IMGT/Automat (23, 24) and IMGT/Collier-de-Perles
tool (29), IMGT/HighV-QUEST, the high-throughput ver-
sion for next-generation sequencing (NGS) (20, 25, 26),
IMGT/DomainGapAlign (12, 27, 28) for amino acid (AA)
sequence analysis, IMGT/3Dstructure-DB for 3D structures (11–
13) and its extension, IMGT/2Dstructure-DB (for antibodies
and other proteins for which the 3D structure is not avail-
able). IMGT® tools and databases run against IMGT reference
directories built from sequences annotated in IMGT/LIGM-DB
(9), the IMGT® nucleotide database (175,406 sequences from 346
species in November 2013) and from IMGT/GENE-DB (10), the
IMGT® gene database (3,117 genes and 4,732 alleles from 17
species, of which 695 genes and 1,420 alleles for Homo sapiens
and 868 genes and 1,318 alleles for Mus musculus in November
2013).
An interface, IMGT/mAb-DB (14), has been developed
to provide an easy access to therapeutic antibody AA
sequences (links to IMGT/2Dstructure-DB) and structures
(links to IMGT/3Dstructure-DB, if 3D structures are available).
IMGT/mAb-DB data include monoclonal antibodies (mAb, INN
suffix -mab; a -mab is defined by the presence of at least an IG
variable domain) and fusion proteins for immune applications
(FPIA, INN suffix -cept) (a -cept is defined by a receptor fused to
an Fc) from the WHO–INN Programme (50, 51). This database
also includes a few composite proteins for clinical applications
(CPCA) (e.g., protein or peptide fused to an Fc for only increasing
their half-life, identified by the INN prefix ef-) and some related
proteins of the immune system (RPI) used, unmodified, for clini-
cal applications. The unified IMGT® approach is of major interest
for bridging knowledge from IG and TR repertoire in normal and
pathological situations (71–74), IG allotypes and immunogenic-
ity (75–77), NGS repertoire (25, 26), antibody engineering, and
humanization (35, 42–44, 46, 78–82).
IMGT-ONTOLOGY CONCEPTS
IDENTIFICATION: IMGT® STANDARDIZED KEYWORDS
More than 325 IMGT® standardized keywords (189 for sequences
and 137 for 3D structures) were precisely defined (59). They rep-
resent the controlled vocabulary assigned during the annotation
process and allow standardized search criteria for querying the
IMGT® databases and for the extraction of sequences and 3D
structures. They have been entered in BioPortal at the National
Center for Biomedical Ontology (NCBO) in 20102.
Standardized keywords are assigned at each step of the molecu-
lar synthesis of an IG. Those assigned to a nucleotide sequence are
found in the “DE” (definition) and “KW” (keyword) lines of the
IMGT/LIGM-DB files (9). They characterize for instance the gene
type, the configuration type and the functionality type (59). There
are six gene types: variable (V), diversity (D), joining (J), constant
(C), conventional-with-leader, and conventional-without-leader.
Four of them (V, D, J, and C) identify the IG and TR genes and are
specific to immunogenetics. There are four configuration types:
germline (for the V, D, and J genes before DNA rearrangement),
rearranged (for the V, D, and J genes after DNA rearrangement),
partially-rearranged (for D gene after only one DNA rearrange-
ment) and undefined (for the C gene and for the conventional
genes that do not rearrange). The functionality type depends on
the gene configuration. The functionality type of genes in germline
or undefined configuration is functional (F), open reading frame
(ORF), or pseudogene (P). The functionality type of genes in
rearranged or partially-rearranged configuration is either produc-
tive [no stop codon in the V–(D)–J-region and in-frame junction]
2http://bioportal.bioontology.org/ontologies/1491
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or unproductive [stop codon(s) in the V–(D)–J-region, and/or
out-of-frame junction].
The 20 usual AA have been classified into 11 IMGT physic-
ochemical classes (IMGT®, see footnote text 1, IMGT Edu-
cation>Aide-mémoire>Amino acids). The AA changes are
described according to the hydropathy (3 classes), volume (5
classes), and IMGT physicochemical classes (11 classes) (31). For
example, Q1> E (++−) means that in the AA change (Q> E),
the two AA at codon 1 belong to the same hydropathy (+) and
volume (+) classes but to different IMGT physicochemical prop-
erties (−) classes (31). Four types of AA changes are identified in
IMGT®: very similar (+++), similar (++−,+−+), dissimilar
(−−+,−+−,+−−), and very dissimilar (−−−).
DESCRIPTION: IMGT® STANDARDIZED LABELS
More than 560 IMGT® standardized labels (277 for sequences
and 285 for 3D structures) were precisely defined (60). They are
written in capital letters (no plural) to be recognizable without
creating new terms. Standardized labels assigned to the descrip-
tion of sequences are found in the “FT” (feature) lines of the
IMGT/LIGM-DB files (9). Querying these labels represents a
big plus compared to the generalist nucleotide databases [Gen-
Bank/European Nucleotide Archive (ENA)/DNA Data Bank of
Japan (DDBJ)]. Thus it is possible to query for the “CDR3-IMGT”
of the human rearranged productive sequences of IG-Heavy-
Gamma (e.g., 1733 CDR3-IMGT obtained, with their sequences at
the nucleotide or AA level). The core labels include V-REGION, D-
REGION, J-REGION, and C-REGION, which correspond to the
coding region of the V, D, J, and C genes. IMGT structure labels
for chains and domains and their correspondence with sequence
labels are shown for human IG (Table 1), for human TR (Table 2),
and for MH (8) (Table 3). These labels are necessary for a standard-
ized description of the IG, TR, and MH sequences and structures
in databases and tools (60).
Highly conserved AA at a given position in a domain have
IMGT labels (60). Thus three AA labels are common to the V and
C-domains: 1st-CYS (cysteine C at position 23), CONSERVED-
TRP (tryptophan W at position 41), and 2nd-CYS (C at position
104) (62–66). Two other labels are characteristics of the IG and TR
V-DOMAIN and correspond to the first AA of the canonical F/W–
G–X–G motif (where F is phenylalanine, W tryptophan, G glycine,
and X any AA) encoded by the J-REGION: J-PHE or J-TRP (F or
W at position 118) (62–64, 66).
CLASSIFICATION: IMGT® STANDARDIZED GENES AND ALLELES
The IMGT-ONTOLOGY CLASSIFICATION axiom was the trig-
ger of immunoinformatics’ birth. Indeed the IMGT® concepts
of classification allowed, for the first time, to classify the antigen
receptor genes (IG and TR) for any locus [e.g., immunoglob-
ulin heavy (IGH), T cell receptor alpha (TRA)], for any gene
configuration (germline, undefined, or rearranged), and for any
species (from fishes to humans). In higher vertebrates, there are
seven IG and TR major loci (other loci correspond to chromo-
somal orphon sets, genes of which are orphons, not used in the
IG or TR chain synthesis). The IG major loci include the IGH,
and for the light chains, the immunoglobulin kappa (IGK), and
the immunoglobulin lambda (IGL) in higher vertebrates, and the
immunoglobulin iota (IGI) in fishes (IMGT®, see footnote text 1,
IMGT Repertoire).
Since the creation of IMGT® in 1989, at New Haven dur-
ing the Tenth Human Genome Mapping Workshop (HGM10),
the standardized classification and nomenclature of the IG and
TR of humans and other vertebrate species have been under the
responsibility of the IMGT Nomenclature Committee (IMGT-
NC). IMGT® gene and allele names are based on the concepts
of classification of “Group,”“Subgroup,”“Gene,” and “Allele” (61).
“Group” allows to classify a set of genes that belong to the same
multigene family, within the same species or between different
species. For example, there are 10 groups for the IG of higher
vertebrates: IGHV, IGHD, IGHJ, IGHC, IGKV, IGKJ, IGKC, IGLV,
IGLJ, IGLC. “Subgroup” allows to identify a subset of genes, which
belong to the same group, and which, in a given species, share
at least 75% identity at the nucleotide level, e.g., Homo sapiens
IGHV1 subgroup. Subgroups, genes, and alleles are always asso-
ciated to a species name. An allele is a polymorphic variant of
a gene, which is characterized by the mutations of its sequence
at the nucleotide level, identified in its core sequence and com-
pared to the gene allele reference sequence, designated as allele
*01. For example, Homo sapiens IGHV1-2*01 is the allele *01 of
the Homo sapiens IGHV1-2 gene that belongs to the Homo sapi-
ens IGHV1 subgroup, which itself belongs to the IGHV group.
For the IGH locus, the constant genes are designated by the letter
(and eventually number) corresponding to the encoded isotypes
(IGHM, IGHD, IGHG3. . .), instead of using the letter C. IG and
TR genes and alleles are not italicized in publications. IMGT-
ONTOLOGY concepts of classification have been entered in the
NCBO BioPortal.
The IMGT® IG and TR gene names (2–5) were approved by the
Human Genome Organisation (HUGO) Nomenclature Commit-
tee (HGNC) in 1999 (83, 84) and were endorsed by the WHO–IUIS
Nomenclature Subcommittee for IG and TR (48, 49). The IMGT®
IG and TR gene names are the official international reference
and, as such, have been entered in IMGT/GENE-DB (10), in the
Genome Database (GDB) (85), in LocusLink at the National Cen-
ter for Biotechnology Information (NCBI) USA (86), in Entrez
Gene (NCBI) when this database (now designated as “Gene”)
superseded LocusLink (87), in NCBI MapViewer, in Ensembl at
the European Bioinformatics Institute (EBI) (88), and in the Ver-
tebrate Genome Annotation (Vega) Browser (89) at the Wellcome
Trust Sanger Institute (UK). HGNC, Gene NCBI, Ensembl, and
Vega have direct links to IMGT/GENE-DB (10). IMGT® human
IG and TR genes were also integrated in IMGT-ONTOLOGY on
the NCBO BioPortal and, on the same site, in the HUGO ontology
and in the National Cancer Institute (NCI) Metathesaurus. AA
sequences of human IG and TR constant genes (e.g., Homo sapi-
ens IGHM, IGHG1, IGHG2) were provided to UniProt in 2008.
Since 2007, IMGT® gene and allele names have been used for the
description of the therapeutic mAb and FPIA of the WHO–INN
Programme (50, 51).
The basis for the nomenclature of the MH of newly sequenced
genomes has been set up on the same concepts. In IMGT®, MHC
refers to the locus, which indeed is a complex of genes, particularly
in the higher vertebrates. In contrast the letter“C”is dropped when
referring to individual genes and proteins. Thus, the class I genes
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Table 1 | Immunoglobulin (IG) receptor, chain, and domain structure labels and correspondence with sequence labels.
IG structure labels (IMGT/3Dstructure-DB) Sequence labels
(IMGT/LIGM-DB)
Receptora Chainb Domain description type Domainc Region
IG-GAMMA-1_KAPPA L-KAPPA V-DOMAIN V-KAPPA V–J-REGION
C-DOMAIN C-KAPPA C-REGION
H-GAMMA-1 V-DOMAIN VH V–D–J-REGION
C-DOMAIN CH1 C-REGIONd
C-DOMAIN CH2
C-DOMAIN CH3
IG-MU_LAMBDA L-LAMBDA V-DOMAIN V-LAMBDA V–J-REGION
C-DOMAIN C-LAMBDA-1 C-REGION
H-MU V-DOMAIN VH V–D–J-REGION
C-DOMAIN CH1 C-REGIONd
C-DOMAIN CH2
C-DOMAIN CH3
C-DOMAIN CH4e
aLabels are shown for two examples of IG (Homo sapiens IgG1-kappa and IgM-lambda). An IG (“Receptor”) (Figure 1) is made of two identical heavy (H, for IG-HEAVY)
chains and two identical light (L, for IG-LIGHT) chains (“Chain”) and usually comprises 12 (e.g., IgG1) or 14 (e.g., IgM) domains. Each chain has an N-terminalV-DOMAIN
(or V–(D)–J-REGION, encoded by the rearranged V–(D)–J genes), whereas the remaining of the chain is the C-REGION (encoded by a C gene). The IG C-REGION
comprises one C-DOMAIN (C-KAPPA or C-LAMBDA) for the L chain, or several C-DOMAIN (CH) for the H chain (2).
bThe kappa (L-KAPPA) or lambda (L-LAMBDA) light chains may associate to any heavy chain isotype (e.g., H-GAMMA-1, H-MU). In humans, there are nine isotypes,
H-MU, H-DELTA, H-GAMMA-3, H-GAMMA-1, H-ALPHA-1, H-GAMMA-2, H-GAMMA-4, H-EPSILON, H-ALPHA-2 (listed in the order 5′–3′ in the IGH locus of the IGHC
genes, which encode the constant region of the heavy chains (2) (IMGT® http/ /www.imgt.org, IMGT Repertoire).
cThe IG V-DOMAIN includes VH (for the IG heavy chain) and VL (for the IG light chain). In higher vertebrates, the VL is V-KAPPA or V-LAMBDA, whereas in fishes, the
VL is V-IOTA. The C-DOMAIN includes CH [for the IG heavy chain, the number of CH per chain depending on the isotype (2)] and CL (for the IG light chain). In higher
vertebrates, the CL is C-KAPPA or C-LAMBDA, whereas in fishes, the CL is C-IOTA.
dThe heavy chain C-REGION also includes the HINGE-REGION for the H-ALPHA, H-DELTA, and H-GAMMA chains and, for membrane IG (mIG), the CONNECTING-
REGION (CO), TRANSMEMBRANE-REGION (TM) and CYTOPLASMIC-REGION (CY); for secreted IG (sIG), the C-REGION includes CHS instead of CO, TM,
and CY.
eFor H-MU and H-EPSILON.
are designated as MH1 whereas the class II genes are designated as
MH2. The IMGT nomenclature, with the MH1 and MH2 groups,
has been used for the first time with the Oncorhynchus mykiss
genes [see footnote text 1, IMGT Repertoire (MH)> Locus and
genes>Gene tables]. It can also be applied to the human genes in
databases, which deal with humans and other vertebrate species
(for example, Homo sapiens MH1-A for HLA-A).
NUMEROTATION: IMGT UNIQUE NUMBERING AND IMGT COLLIER de
PERLES
The IMGT-ONTOLOGY NUMEROTATION axiom is acknowl-
edged as the“IMGT® Rosetta stone”that has bridged the biological
and computational spheres in bioinformatics (40). The IMGT®
concepts of numerotation comprise the IMGT unique numbering
(8, 62–66) and its graphical 2D representation the IMGT Col-
lier de Perles (67–70). Developed for and by the “domain,” these
concepts integrate sequences, structures, and interactions into a
standardized domain-centric knowledge for functional genomics.
The IMGT unique numbering has been defined for the variable V-
domain (V-DOMAIN of the IG and TR, and V-LIKE-DOMAIN of
IgSF other than IG and TR) (62–64), the constant C-domain (C-
DOMAIN of the IG and TR, and C-LIKE-DOMAIN of IgSF other
than IG and TR) (65), and the groove G-domain (G-DOMAIN
of the MH, and G-LIKE-DOMAIN of MhSF other than MH) (8,
90, 91). Thus the IMGT unique numbering and IMGT Collier
de Perles provide a definitive and universal system across species
including invertebrates, for the sequences and structures of the V,
C, and G-domains of IG, TR, MH, IgSF, and MhSF (66, 70, 92, 93).
V-domain IMGT® definitive system
V-domain definition and main characteristics. In the IMGT®
definitive system, the V-domain includes the V-DOMAIN of the
IG and of the TR, which corresponds to the V–J-REGION or V–D–
J-REGION encoded by V–(D)–J rearrangements (2, 3), and the V-
LIKE-DOMAIN of the IgSF other than IG and TR. The V-domain
description of any receptor, any chain, and any species is based
on the IMGT unique numbering for V-domain (V-DOMAIN and
V-LIKE-DOMAIN) (62–64, 66).
A V-domain (Figure 3) comprises about 100 AA and is made
of nine antiparallel beta strands (A, B, C, C′, C′′, D, E, F, and G)
linked by beta turns (AB, CC′, C′′D, DE, and EF), and three loops
(BC, C′C′′, and FG), forming a sandwich of two sheets [ABED]
[GFCC′C′′] (62–64, 66). The sheets are closely packed against
each other through hydrophobic interactions giving a hydrophobic
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Table 2 |T cell receptor (TR), chain, and domain structure labels and correspondence with sequence labels.
TR structure labels (IMGT/3Dstructure-DB) Sequence labels
(IMGT/LIGM-DB)
Receptora Chain Domain description type Domainb Region
TR-ALPHA_BETA TR-ALPHA V-DOMAIN V-ALPHA V–J-REGION
C-DOMAIN C-ALPHA Part of C-REGIONc
TR-BETA V-DOMAIN V-BETA V–D–J-REGION
C-DOMAIN C-BETA Part of C-REGIONc
TR-GAMMA_DELTA TR-GAMMA V-DOMAIN V-GAMMA V–J-REGION
C-DOMAIN C-GAMMA Part of C-REGIONc
TR-DELTA V-DOMAIN V-DELTA V–D–J-REGION
C-DOMAIN C-DELTA Part of C-REGIONc
aA TR (“Receptor”) (3) (Figure 2) is made of two chains (alpha and beta, or gamma and delta) (“Chain”) and comprises four domains. Each chain has an N-terminal
V-DOMAIN [or V–(D)–J-REGION, encoded by the rearranged V–(D)–J genes (3)] whereas the remaining of the chain is the C-REGION (encoded by a C gene). The TR
C-REGION comprises one C-DOMAIN (3). TR receptor, chain, and domain structure labels, and correspondence with sequence labels, are shown for two examples
of TR (Homo sapiens TR-alpha_beta and TR-gamma_delta).
bThe TR V-DOMAIN includes V-ALPHA, V-BETA, V-GAMMA, and V-DELTA. The TR C-DOMAIN includes C-ALPHA, C-BETA, C-GAMMA, and C-DELTA (there are two
isotypes for the TR-BETA and TR-GAMMA chains in humans, TR-BETA-1 and TR-BETA-2, and TR-GAMMA-1 and TR-GAMMA-2, the C-REGION of these chains being
encoded by the TRBC1 and TRBC2 genes, and TRGC1 and TRGC2 genes, respectively) (IMGT® http:// www.imgt.org, IMGT Repertoire) (3).
cTheTR chain C-REGION also includes the CONNECTING-REGION (CO), theTRANSMEMBRANE-REGION (TM), and the CYTOPLASMIC-REGION (CY), which are not
present in 3D structures.
Table 3 | Major histocompatibility (MH) receptor, chain, and domain structure labels and correspondence with sequence labels.
MH group MH structure labels (IMGT/3Dstructure-DB) Sequence labels
(IMGT/LIGM-DB)
Receptora Chain Domain description typeb Domain Domain number Region
MH1 MH1-ALPHA_B2M I-ALPHA G-DOMAIN G-ALPHA1 [D1] Part of REGIONc
G-DOMAIN G-ALPHA2 [D2]
C-LIKE-DOMAIN C-LIKE [D3]
B2M C-LIKE-DOMAIN C-LIKE [D] REGION
MH2 MH2-ALPHA_BETA II-ALPHA G-DOMAIN G-ALPHA [D1] Part of REGIONc
C-LIKE-DOMAIN C-LIKE [D2]
II-BETA G-DOMAIN G-BETA [D1] Part of REGIONc
C-LIKE-DOMAIN C-LIKE [D2]
aAn MH (“Receptor”) (8) depending on the MH group is made of one chain (I-ALPHA) non-covalently associated to the beta2-microglobulin (B2M) (MH1 group, in
the literature MHC class I) (Figure 2) or of two chains (II-ALPHA and II-BETA) (MH2 group, in the literature MHC class II). The I-ALPHA chain has two G-DOMAIN
whereas each II-ALPHA and II-BETA has one G-DOMAIN. MH receptor, chain, and domain structure labels, and correspondence with sequence labels, are shown for
examples of members of the MH1 and MH2 groups.
bThe domain description type shows that the MH proteins belong to the MhSF by their G-DOMAIN and to the IgSF by their C-LIKE-DOMAIN. The B2M associated to
the I-ALPHA chain in MH1 has only a single C-LIKE-DOMAIN and only belongs to the IgSF.
cThe REGION of the I-ALPHA, II-ALPHA, and II-BETA chains also includes the CONNECTING-REGION (CO), the TRANSMEMBRANE-REGION (TM), and the
CYTOPLASMIC-REGION (CY), which are not present in 3D structures.
core, and joined together by a disulfide bridge between a first highly
conserved cysteine (1st-CYS) in the B strand (in the first sheet) and
a second equally conserved cysteine (2nd-CYS) in the F strand (in
the second sheet) (62–64, 66).
V-domain strands and loops (FR-IMGT and CDR-IMGT). The
V-domain strands and loops and their delimitations and lengths,
based on the IMGT unique numbering for V-domain (62–64, 66),
are shown in Table 4. In the IG and TR V-DOMAIN, the three
hypervariable loops BC, C′C′′, and FG involved in the ligand recog-
nition (native antigen for IG and pMH for TR) are designated
complementarity determining regions (CDR-IMGT), whereas the
strands form the framework region (FR-IMGT), which includes
FR1-IMGT, FR2-IMGT, FR3-IMGT, and FR4-IMGT (Table 4). In
the IMGT® definitive system, the CDR-IMGT have accurate and
unambiguous delimitations in contrast to the CDR described in
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FIGURE 3 |Variable (V) domain. An IG VH (V-DOMAIN) is shown as an
example. (A) 3D structure ribbon representation with the IMGT strand and
loop delimitations (64). (B) IMGT Collier de Perles on two layers with
hydrogen bonds. The IMGT Collier de Perles on two layers show, in the
forefront, the GFCC’C” strands (forming the sheet located at the interface
VH/VL of the IG) and, in the back, the ABED strands. The IMGT Collier de
Perles with hydrogen bonds (green lines online, only shown here for the
GFCC′C′′ sheet) is generated by the IMGT/Collier-de-Perles tool integrated in
IMGT/3Dstructure-DB, from experimental 3D structure data (11–13). (C) IMGT
Collier de Perles on two layers generated from IMGT/DomainGapAlign (12,
27, 28). Pink circles (online) indicate amino acid (AA) changes compared to
the closest genes and alleles from the IMGT reference directory. (D) IMGT
Collier de Perles on one layer. AA are shown in the one-letter abbreviation. All
proline (P) are shown online in yellow. IMGT anchors are in square. Hatched
circles are IMGT gaps according to the IMGT unique numbering for V-domain
(64, 66). Positions with bold (online red) letters indicate the four conserved
positions that are common to a V-domain and to a C-domain: 23 (1st-CYS), 41
(CONSERVED-TRP), 89 (hydrophobic), 104 (2nd-CYS) (62–66), and the fifth
conserved position, 118 (J-TRP or J-PHE), which is specific to a V-DOMAIN
(Continued)
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FIGURE 3 | Continued
and belongs to the motif F/W-G-X-G that characterizes the J-REGION (64,
66) (Table 4). The hydrophobic AA (hydropathy index with positive value: I,
V, L, F, C, M, A) and tryptophan (W) (31) found at a given position in more
than 50% of sequences are shown (online with a blue background color).
Arrows indicate the direction of the beta strands and their designations in
3D structures. IMGT color menu for the CDR-IMGT of a V-DOMAIN
indicates the type of rearrangement, V–D–J (for a VH here, red, orange,
and purple) or V–J (for V-KAPPA or V-LAMBDA (not shown), blue, green,
and greenblue) (2). The identifier of the chain to which the VH domain
belongs is 1n0x_H (from the Homo sapiens b12 Fab) in
IMGT/3Dstructure-DB (http://www.imgt.org). The CDR-IMGT lengths of
this VH are [8.8.20] and the FR-IMGT are [25.17.38.11]. The 3D ribbon
representation was obtained using PyMOL (http://www.pymol.org) and
“IMGT numbering comparison” of 1n0x_H (VH) from
IMGT/3Dstructure-DB (http://www.imgt.org).
Table 4 |V-domain strands and loops, IMGT positions, and lengths, based on the IMGT unique numbering forV-domain (V-DOMAIN and
V-LIKE-DOMAIN).
V-domain strands
and loopsa
IMGT positionsb Lengthsc Characteristic IMGT
Residue@Positiond
V-DOMAIN FR-IMGT
and CDR-IMGT
A-STRAND 1–15 15 (14 if gap at 10) FR1-IMGT
B-STRAND 16–26 11 1st-CYS 23
BC-LOOP 27–38 12 (or less) CDR1-IMGT
C-STRAND 39–46 8 CONSERVED-TRP 41 FR2-IMGT
C′-STRAND 47–55 9
C′C′′-LOOP 56–65 10 (or less) CDR2-IMGT
C′′-STRAND 66–74 9 (or 8 if gap at 73) FR3-IMGT
D-STRAND 75–84 10 (or 8 if gaps at 81, 82)
E-STRAND 85–96 12 Hydrophobic 89
F-STRAND 97–104 8 2nd-CYS 104
FG-LOOP 105–117 13 (or less, or more) CDR3-IMGT
G-STRAND 118–128 11 (or 10) V-DOMAIN J-PHE 118
or J-TRP 118e
FR4-IMGT
aIMGT® labels (concepts of description) are written in capital letters (no plural) (60). Beta turns (AB, CC′, C′′D, DE, or EF) are individualized only if they have additional
AA compared to the standard description. If not, they are included in the strands.
bBased on the IMGT unique numbering for V-domain (V-DOMAIN and V-LIKE-DOMAIN) (62–64, 66).
cIn number of AA (or codons).
dIMGT Residue@Position is a given residue (usually an AA) or a given conserved property AA class, at a given position in a domain, based on the IMGT unique
numbering (66).
eIn the IG and TR V-DOMAIN, the G-STRAND (or FR4-IMGT) is the C-terminal part of the J-REGION, with J-PHE or J-TRP 118, and the canonical motif F/W–G–X–G
at positions 118–121 (2, 3). The JUNCTION refers to the CDR3-IMGT plus the two anchors 2nd-CYS 104 and J-PHE or J-TRP 118 (63, 64). The JUNCTION (positions
104–118) is therefore two AA longer than the corresponding CDR3-IMGT (positions 105–117) (63, 64).
the literature. Correspondences between the IMGT unique num-
bering with other numberings, e.g., Kabat (94) or Chothia (95),
are available in the IMGT Scientific chart. The correspondences
with these previous and heterogenous numberings are useful for
the interpretation of previously published data but nowadays the
usage of these numberings has become obsolete owing to the
development of immunoinformatics based on the IMGT® stan-
dards (8, 62–70) (IMGT®, see footnote text 1, IMGT Scientific
chart>Numbering>Correspondence between V numberings).
For a V-domain, the BC loop (or CDR1-IMGT in a V-
DOMAIN) encompasses positions 27–38, the C′C′′ loop (or
CDR2-IMGT in a V-DOMAIN) positions 56–65, and the FG
loop (or CDR3-IMGT) positions 105–117. In a V-DOMAIN, the
CDR3-IMGT encompasses the V–(D)–J junction that results from
a V–J or V–D–J rearrangement (2, 3) and is more variable in
sequence and length than the CDR1-IMGT and CDR2-IMGT that
are encoded by the V gene region only. For CDR3-IMGT of length
>13 AA, additional IMGT positions are added at the top of the
loop between 111 and 112 (Table 5).
IMGT Colliers de Perles. The loop and strands are visualized
in the IMGT Colliers de Perles (67–70), which can be displayed
on one layer (closer to the AA sequence) or on two layers (closer
to the 3D structure) (Figure 3). The three loops, BC, C′C′′, and
FG (or CDR1-IMGT, CDR2-IMGT, and CDR3-IMGT for a V-
DOMAIN) are delimited by the IMGT anchors, which are shown
in square in the IMGT Colliers de Perles. IMGT anchors are
positions, which belong to strands and represent anchors for the
loops of the V-domains. IMGT anchors are the key and original
concept of IMGT®, which definitively solved the ambiguous sit-
uation of different CDR lengths and delimitations found in the
literature. The six anchors of a V-domain are positions 26 and
39 (anchors of the BC loop or CDR1-IMGT in V-DOMAIN),
55 and 66 (anchors of the C′–C′′ loop or CDR2-IMGT in V-
DOMAIN), 104 and 118 (anchors of the FG loop or CDR3-IMGT
in V-DOMAIN). The CDR3-IMGT anchors are highly conserved,
they are C104 (2nd-CYS, in F strand) and F118 or W118 (J-
PHE or J-TRP in G strand). The JUNCTION of an IG or TR
V-DOMAIN includes the anchors 104 and 118, and is therefore
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Table 5 | IMGT additional positions for CDR3-IMGT.
CDR3-IMGT
lengths
IMGT additional positions for CDR3-IMGT
length >13 AAa
21 111 111.1 111.2 111.3 111.4 112.4 112.3 112.2 112.1 112
20 111 111.1 111.2 111.3 – 112.4 112.3 112.2 112.1 112
19 111 111.1 111.2 111.3 – – 112.3 112.2 112.1 112
18 111 111.1 111.2 – – – 112.3 112.2 112.1 112
17 111 111.1 111.2 – – – – 112.2 112.1 112
16 111 111.1 – – – – – 112.2 112.1 112
15 111 111.1 – – – – – – 112.1 112
14 111 – – – – – – – 112.1 112
aFor CDR3-IMGT length >13 AA, IMGT additional positions are created between
positions 111 and 112 at the top of the CDR3-IMGT loop in the following order
112.1, 111.1, 112.2, 111.2, 112.3, 111.3, etc., and as many positions can be added as
necessary for very long CDR3-IMGT. For CDR3-IMGT length <13 AA (not shown),
IMGT gaps are created classically from the top of the loop, in the following order
111, 112, 110, 113, 109, 114, etc. (IMGT® http:// www.imgt.org, IMGT Scientific
chart>Numbering).
two AA longer than the corresponding CDR3-IMGT (positions
105–117).
In biological data, the lengths of the loops and strands are given
by the number of occupied positions [unoccupied positions or
“IMGT gaps” are represented with hatches in the IMGT Colliers
de Perles (Figure 3) or by dots in alignments]. The CDR-IMGT
lengths are given in number of AA (or codons), into brackets and
separated by dots: for example [9.6.9] means that the BC, C′C′′,
and FG loops (or CDR1-IMGT, CDR2-IMGT, and CDR3-IMGT
for a V-DOMAIN) have a length of 9, 6, and 9 AA (or codons),
respectively. Similarly [25.17.38.11] means that the FR1-IMGT,
FR2-IMGT, FR3-IMGT, and FR4-IMGT have a length of 25, 17,
38, and 11 AA (or codons), respectively. Together, the four FR of a
VH domain usually comprise 91 AA and the individual FR-IMGT
lengths are [25.17.38.11], whereas the four FR of a VL domain
usually comprise 89 AA and the individual FR-IMGT lengths are
[26.17.36.10].
Conserved AA. A V-domain has five characteristic AA at given
positions (positions with bold (online red) letters in the IMGT
Colliers de Perles). Four of them are highly conserved and
hydrophobic (31) and are common to the C-domain: 23 (1st-CYS),
41 (CONSERVED-TRP), 89 (hydrophobic), and 104 (2nd-CYS).
These AA contribute to the two major features shared by the V
and C-domain: the disulfide bridge (between the two cysteines
23 and 104) and the internal hydrophobic core of the domain
(with the side chains of tryptophan W41 and AA 89). The fifth
position, 118, is an anchor of the FG loop. It is occupied, in
the V-domains of IgSF other than IG or TR, by AA with diverse
physicochemical properties (31). In contrast, in IG and TR V-
DOMAIN, the position 118 is occupied by remarkably conserved
AA, which consist in a phenylalanine or a tryptophan encoded
by the J-REGION and therefore designated J-TRP or J-PHE 118.
The bulky aromatic side chains of J-TRP and J-PHE are inter-
nally orientated and structurally contribute to the V-DOMAIN
hydrophobic core (64).
Genomic delimitation. A last criterion used in the IMGT®
definitive system for the characterization of a V-domain is its
delimitation taking into account the exon delimitations, when-
ever appropriate. The exon rule is not used for the delimitation
of the 5′ end of the first N-terminal domain of proteins with a
leader (this includes the V-DOMAIN of the IG and TR chains).
In those cases, the 5′end of the first N-terminal domain of the
chain corresponds to the proteolytic site between the leader (L-
REGION) and the coding region of the mature protein. The IG
and TR V-DOMAIN is therefore delimited in 5′ by a proteolytic
site and in 3′ at the genomic level by the splicing site of the
J-REGION (60). This IMGT® genomic approach integrates the
strands A and G, in contrast to structural alignments that usu-
ally lack these strands due to their poor structural conservation,
and thus bridges the gap between genomic data (exon) and 3D
structure (domain).
C-domain IMGT® definitive system
C-domain definition and main characteristics. In the IMGT®
definitive system, the C-domain includes the C-DOMAIN of the
IG and of the TR (2, 3) and the C-LIKE-DOMAIN of the IgSF other
than IG and TR. The C-domain description of any receptor, any
chain, and any species is based on the IMGT unique numbering
for C-domain (C-DOMAIN and C-LIKE-DOMAIN) (65, 66).
A C-domain (Figure 4) comprises about 90–100 AA and is
made of seven antiparallel beta strands (A, B, C, D, E, F, and G),
linked by beta turns (AB, DE, and EF), a transverse strand (CD)
and two loops (BC and FG), and forming a sandwich of two sheets
(ABED) (GFC) (65, 66). A C-domain has a topology and a three-
dimensional structure similar to that of a V-domain but without
the C′ and C′′ strands and the C′C′′ loop, which is replaced by a
transverse CD strand (65).
C-domain strands and loops. The C-domain strands, turns, and
loops and their delimitations and lengths, based on the IMGT
unique numbering for C-domain (65, 66), are shown in Table 6.
Correspondences between the IMGT unique numbering with
other numberings (Eu, Kabat) are available in the IMGT Scientific
chart. The correspondences with these previous numberings are
useful for the interpretation of previously published data but, as for
the V-domain, the usage of these previous numberings has become
obsolete owing to the development of immunoinformatics based
on the IMGT® standards (8, 62–70) (IMGT®, see footnote text 1,
IMGT Scientific chart>Numbering>Correspondence between
C numberings).
IMGT Colliers de Perles. The lengths of the strands and loops are
visualized in the IMGT Colliers de Perles (68–70), on one layer and
two layers (Figure 4). There are six IMGT anchors in a C-domain
(four of them identical to those of a V-domain): positions 26 and
39 (anchors of the BC loop), 45 and 77 [by extension, anchors of
the CD strand as there is no C′–C′′ loop in a C-domain (65)], and
104 and 118 (anchors of the FG loop).
Conserved AA. A C-domain has five characteristic AA at given
positions [positions with bold (online red) letters in the IMGT
Colliers de Perles]. Four of them are highly conserved and
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FIGURE 4 | Constant (C) domain. An IG CH (C-DOMAIN) is shown as an
example. (A) 3D structure ribbon representation with the IMGT strand and
loop delimitations (65). (B) IMGT Collier de Perles on two layers with
hydrogen bonds. The IMGT Colliers de Perles on two layers show, in the
forefront, the GFC strands and, in the back, the ABED strands (located at the
interface CH1/CL of the IG), linked by the CD transverse strand. The IMGT
Collier de Perles with hydrogen bonds (green lines online, only shown here for
the GFC sheet) is generated by the IMGT/Collier-de-Perles tool integrated in
IMGT/3Dstructure-DB, from experimental 3D structure data (11–13). (C) IMGT
Collier de Perles on two layers from IMGT/DomainGapAlign (12, 27, 28).
(D) IMGT Colliers de Perles on one layer. Amino acids are shown in the
one-letter abbreviation. All proline (P) are shown online in yellow. IMGT
anchors are in square. Hatched circles are IMGT gaps according to the IMGT
unique numbering for C-domain (65, 66). Positions with bold (online red)
letters indicate the four conserved positions that are common to a V-domain
(Continued)
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FIGURE 4 | Continued
and to a C-domain: 23 (1st-CYS), 41 (CONSERVED-TRP), 89 (hydrophobic),
104 (2nd-CYS) (62–66) (Table 6), and position 118, which is only conserved in
V-DOMAIN. The identifier of the chain to which the CH domain belongs is
1n0x_H (from the Homo sapiens b12 Fab, in IMGT/3Dstructure-DB,
http://www.imgt.org). The 3D ribbon representation was obtained using
PyMOL and “IMGT numbering comparison” of 1n0x_H (CH1) from
IMGT/3Dstructure-DB (http://www.imgt.org).
Table 6 | C-domain strands, turns, and loops, IMGT positions, and
lengths, based on the IMGT unique numbering for C-domain
(C-DOMAIN and C-LIKE-DOMAIN).
C-domain strands,
turns, and loopsa
IMGT
positionsb
Lengthsc Characteristic IMGT
Residue@Positiond
A-STRAND 1–15 15 (14 if
gap at 10)
AB-TURN 15.1–15.3 0–3
B-STRAND 16–26 11 1st-CYS 23
BC-LOOP 27–31 10 (or less)
34–38
C-STRAND 39–45 7 CONSERVED-TRP 41
CD-STRAND 45.1–45.9 0–9
D-STRAND 77–84 8 (or 7 if
gap at 82)
DE-TURN 84.1–84.7 0–14
85.1–85.7
E-STRAND 85–96 12 Hydrophobic 89
EF-TURN 96.1–96.2 0–2
F-STRAND 97–104 8 2nd-CYS 104
FG-LOOP 105–117 13 (or less,
or more)
G-STRAND 118–128 11 (or less)
aIMGT® labels (concepts of description) are written in capital letters (no plural) (60).
bBased on the IMGT unique numbering for C-domain (C-DOMAIN and C-LIKE-
DOMAIN) (65, 66).
cIn number of amino acids (AA) (or codons).
dIMGT Residue@Position is a given residue (usually an AA) or a given conserved
property AA class, at a given position in a domain, based on the IMGT unique
numbering (66).
hydrophobic (31) and are common to the V-domain: 23 (1st-CYS),
41 (CONSERVED-TRP), 89 (hydrophobic), and 104 (2nd-CYS).
As mentioned above, these AA contribute to the two major fea-
tures shared by the V and C-domain: the disulfide bridge (between
the two cysteines 23 and 104) and the internal hydrophobic core
of the domain (with the side chains of tryptophan W41 and AA
89). The fifth position, 118, is diverse and is characterized as being
an FG loop anchor.
Genomic delimitation. In the IMGT® definitive system, the
C-domains (C-DOMAIN and C-LIKE-DOMAIN) are delimited
taking into account the exon delimitation, whenever appropriate.
As for the V-domain, this IMGT® genomic approach integrates
the strands A and G, which are absent of structural alignments.
G-domain IMGT® definitive system
G-domain definition and main characteristics. In the IMGT®
definitive system, the G-domain includes the G-DOMAIN of the
MH (Figure 5) (8, 66) and the G-LIKE-DOMAIN of the MhSF
other than MH or RP1-MH1Like (there is no “RPI-MH2Like”
identified so far) (96, 97). The RPI-MH1Like in humans com-
prise (97): AZGP1 (that regulates fat degradation in adipocytes),
CD1A to CD1E proteins (that display phospholipid antigens to
T cells and participate in immune defense against microbian
pathogens), FCGRT (that transports maternal immunoglobulins
through placenta and governs neonatal immunity), HFE (that
interacts with transferring receptor and takes part in iron home-
ostasis by regulating iron transport through cellular membranes),
MICA and MICB (that are induced by stress and involved in
tumor cell detection), MR1 (that regulates mucosal immunity),
PROCR, previously EPCR (that interacts with activated C pro-
tein and is involved in the blood coagulation pathway), RAET1E,
RAET1G, and RAET1L (that are inducible by retinoic acid and
stimulate cytokine/chemokine production and cytotoxic activity
of NK cells), and ULBP1, ULBP2, and ULBP3 (that are ligands for
NKG2D receptor). The G-domain description of any receptor, any
chain, and any species is based on the IMGT unique numbering
for G-domain (G-DOMAIN and G-LIKE-DOMAIN) (8, 66).
G-domain strands and helix. A G-domain (Figure 5) comprises
about 90 AA and is made of four antiparallel beta strands (A, B,
C, and D) linked by turns (AB, BC, and CD), and of a helix (98,
99); the helix sits on the beta strands, its axis forming an angle of
about 40° with the strands (90, 91). Two G-domains are needed to
form the MhSF groove made of a “floor” and two “walls” (8, 66).
Each G-domain contributes by its four strands and turns to half
of the groove floor and by its helix to one wall of the groove (8,
66, 90, 91). The MH groove in which the peptide binds is made
of two G-DOMAIN belonging to a single chain or to two chains,
depending on the MH group, MH1 or MH2, respectively. In the
MH1, the groove is made of two G-DOMAIN (G-ALPHA1 and
G-ALPHA2), which belong to the same chain I-ALPHA, whereas
in the MH2, the groove is made of two G-DOMAIN (G-ALPHA
and G-BETA), which belong to two different chains, II-ALPHA
and II-BETA, respectively (8, 66). For the RPI-MH1Like, the two
G-LIKE-DOMAIN also belong, as for the MH1, to the same chain
(I-ALPHA-LIKE) (96, 97).
IMGT Colliers de Perles. The G-domain strands, turns, and helix
and their delimitations and lengths, based on the IMGT unique
numbering for G-domain (8, 66) are shown in Table 7. The strands
and helix of each domain are visualized in the IMGT Collier
de Perles (68–70, 90, 91) (Figure 5). The views are from above
the cleft (with the helices displaced to show the floor) and with
on top and on bottom, respectively, G-ALPHA1 and G-ALPHA2
(MH1), G-ALPHA and G-BETA (MH2), and G-ALPHA1-LIKE
and G-ALPHA2-LIKE (RPI-MH1Like). There is no link between
G-ALPHA and G-BETA because they belong to different chains
(II-ALPHA and II-BETA).
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FIGURE 5 | Groove (G) domain. (A) 3D structure ribbon
representation of the two G-domains. The two domains form a groove
with a “floor” (four strands from each domain) and two “walls” (one
helix from each domain) (8). The G-domains characterize the proteins
of the MhSF, which comprises the MH (MH1 and MH2) and the
RPI-MH1Like (MhSF other than MH) (8). The two G-DOMAIN of an
MH1 are shown as an example. The view is from above the cleft with
the G-ALPHA1 (on top) and G-ALPHA2 (on bottom). (B) IMGT Colliers
de Perles of the two G-DOMAIN of an MH1. G-ALPHA1 (on top) and
G-ALPHA2 (on bottom) belong to the I-ALPHA chain (8). (C) IMGT
Colliers de Perles of the two G-DOMAIN of an MH2. G-ALPHA (on
top) and G-BETA (on bottom) to the II-ALPHA chain and to the II-BETA
chain, respectively (8). (D) IMGT Colliers de Perles of the two
G-LIKE-DOMAIN of a RPI-MH1Like. G-ALPHA1-LIKE (on top) and
G-ALPHA2-LIKE (on bottom) belong to the I-ALPHA-LIKE chain.
Helices are moved outside of the floor to make it visible. Amino acids
(AA) are shown in the one-letter abbreviation. All proline (P) are
shown online in yellow. Hatched circles are IMGT gaps according to
the IMGT unique numbering for G-domain (8, 66). The 3D ribbon
representation was obtained using PyMOL and “IMGT numbering
comparison” of 3qfj_A (G-ALPHA1 and G-ALPHA2) in
IMGT/3Dstructure-DB (http://www.imgt.org). IMGT Colliers de Perles
AA sequences are from 3qfj_A for MH1 (Homo sapiens
HLA-A*0201), 1j8h_A and 1j8h_B for MH2 (Homo sapiens
HLA-DRA*0101 and HLA-DRB1*0401, respectively) and 3huj_A for
RPI-MH1Like (Homo sapiens CD1D). The IMGT Colliers de Perles
were generated using the IMGT/Collier-de-Perles tool integrated in
IMGT/3Dstructure-DB (http://www.imgt.org) (11–13).
Conserved AA. Two conserved cysteines, CYS-11 (in the A-
strand) and CYS-74 (in the helix) (Table 7), are found in the
G-ALPHA2, G-BETA, and G-ALPHA2-LIKE (Figure 5), where
they form a disulfide bridge fixing the helix to the floor.
Genomic delimitation. In the IMGT® definitive system, the
G-domains (G-DOMAIN and G-LIKE-DOMAIN) are delim-
ited taking into account the exon delimitations, if appropriate.
Alignment sequence comparison with previously identified genes
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Table 7 | G-domain strands, turns, and helix, IMGT positions, and
lengths, based on the IMGT unique numbering for G-domain
(G-DOMAIN and G-LIKE-DOMAIN).
G-domain
strands, turns,
and helixa
IMGT
positionsb
Lengthsc Characteristic IMGT
Residue@Positiond
and additional
positionse
A-STRAND 1–14 14 7A, CYS-11
AB-TURN 15–17 3 (or 2 or 0)
B-STRAND 18–28 11 (or 10f)
BC-TURN 29–30 2
C-STRAND 31–38 8
CD-TURN 39–41 3 (or 1g)
D-STRAND 42–49 8 49.1–49.5
HELIX 50–92 43 (or less
or more)
54A, 61A, 61B, 72A,
CYS-74, 92A
aIMGT® labels (concepts of description) are written in capital letters (no plural) (60).
bBased on the IMGT unique numbering for G-domain (G-DOMAIN and G-LIKE-
DOMAIN) (8, 66).
cIn number of AA (or codons).
dIMGT Residue@Position is a given residue (usually an AA) or a given conserved
property AA class, at a given position in a domain, based on the IMGT unique
numbering (66).
eFor details on additional positions, see Ref. (8).
fOr 9 in some G-BETA (8).
gOr 0 in some G-ALPHA2-LIKE (8).
is used when genomic data are not available, as recently done
for the rainbow trout (Oncorhynchus mykiss) MH1 and MH2
[IMGT®, see footnote text 1, IMGT Repertoire (MH)>Proteins
and alleles>Protein displays].
IMGT/Collier-de-Perles tool
The IMGT/Collier-de-Perles tool (29), on the IMGT® Web
site at http://www.imgt.org, is a generic tool, which allows the
users to draw IMGT Colliers de Perles (67–70) starting from
their own domain AA sequences [sequences already gapped
according to the IMGT unique numbering, using for example
IMGT/DomainGapAlign (12, 27, 28)] (Table 8). IMGT Collier
de Perles can be obtained for V and C-domains (on one or two
layers) and for G-domains (with one or the two domains of the
groove). IMGT/Collier-de-Perles tool online can be customized to
display the IG and TR CDR-IMGT according to the IMGT color
menu and the AA according to their hydropathy or volume, or to
the 11 IMGT physicochemical classes (31).
IMGT color menu for the CDR-IMGT of a V-DOMAIN indi-
cates the type of rearrangement V–J or V–D–J (2, 3). Thus, the
IMGT color menu for CDR1-IMGT, CDR2-IMGT, and CDR3-
IMGT is red, orange, and purple for the IG VH and for the TR
V-BETA or V-DELTA (encoded by a V–D–J-REGION resulting
from a V–D–J rearrangement), and blue, green, and greenblue
for the IG V-KAPPA or V-LAMBDA and for the TR V-ALPHA
or V-GAMMA (encoded by a V–J-REGION resulting from a V–J
rearrangement). Arbitrarily the red, orange, and purple is used for
the BC, C′C′′ and FG loops of the V-domain of IgSF other than IG
or TR.
The IMGT/Collier-de-Perles tool is integrated in IMGT/
DomainGapAlign (12, 27, 28) (users start from V, C, or G AA
sequences) and in IMGT/V-QUEST (15–20) (users start from
IG and TR V-DOMAIN nucleotide sequences) (Table 8). IMGT
Colliers de Perles for V, C, and G-domains are provided in
IMGT/2Dstructure-DB (for AA sequences in the database), and
in IMGT/3Dstructure-DB (on two layers with hydrogen bonds
for the V or C-domains or with the pMH contact sites for the
G-domains, for 3D structures in the database) (11–13) (Table 8).
IMGT® TOOLS FOR IG, TR, AND MH DOMAIN ANALYSIS
IMGT/V-QUEST
IMGT/V-QUEST for IG and TR V-domain analysis
IMGT/V-QUEST (15–20) is the IMGT® online tool for the
analysis of nucleotide sequences of the IG and TR V-DOMAIN
(Table 8). IMGT/V-QUEST identifies the variable (V), diver-
sity (D), and junction (J) genes in rearranged IG and TR
sequences and, for the IG, the nucleotide (nt) mutations and
AA changes resulting from somatic hypermutations by com-
parison with the IMGT/V-QUEST reference directory. The tool
integrates IMGT/JunctionAnalysis (21, 22) for the detailed char-
acterization of the V–D–J or V–J junctions, IMGT/Automat
(23, 24) for a complete sequence annotation, and IMGT/
Collier-de-Perles (29).
The IMGT/V-QUEST most important functionalities include:
introduction of IMGT gaps in the user nucleotide sequences (and
in its translation), alignments, and identification of the genes
and alleles with the closest germline V, D, and J genes, analy-
sis of the junctions, analysis of somatic hypermutations, and AA
changes and, if the option “Search for insertions and deletions”
was selected, identification of insertions and deletions (indels)
and their correction. Customized parameters and results pro-
vided by IMGT/V-QUEST and IMGT/JunctionAnalysis have been
described elsewhere (15–20).
IMGT/V-QUEST reference directory
The IMGT/V-QUEST reference directory sets against which the
IMGT/V-QUEST is running include IMGT reference sequences
from all functional (F) genes and alleles, all ORF and all in-frame
pseudogenes (P) alleles. By definition, the IMGT reference direc-
tory sets contain one sequence for each allele. By default, the user
sequences are compared with all genes and alleles. However, the
option “With allele *01 only” is useful for: (i) “Detailed view,” if
the user sequences need to be compared with different genes, and
(ii) “Synthesis view,” if the user sequences, which use the same
gene need to be aligned together (independently of the allelic
polymorphism) (17, 19).
The IMGT/V-QUEST reference directories have been set up for
species, which have been extensively studied, such as human and
mouse. This also holds for the other species or taxons with incom-
plete IMGT reference directory sets. In those cases, results should
be interpreted considering the status of the IMGT reference direc-
tory (information on the updates on the IMGT® Web site). Links
to the IMGT/V-QUEST reference directory sets are available from
the IMGT/V-QUEST Welcome page (17, 19).
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Table 8 | IMGT® tools and databases for the analysis of the IG,TR, and MH domains (http://www.imgt.org).
IMGT® tools Results forV, C, or G-domainsa Entry types and protocol references
IMGT/Collier-de-Perles (29) Graphical 2D representation of IMGT Colliers de
Perles (67–70)
User “IMGT gapped” V, C, or G-domain amino
acid (AA) sequences (one sequence per
representation, two possible for G) (29)
IG ANDTR REPERTOIRE ANALYSIS
IMGT/V-QUEST (15–20) 1. Introduction of IMGT gaps User nucleotide sequences of V-DOMAIN (1–50
sequences per analysis, and 1–10 sequences
with the option “Search for insertions and
deletions”) (19)
2. Identification of the closest V, D, and J genes
and alleles
3. IMGT/JunctionAnalysis results (21, 22)
4. Description of mutations and AA changes Applications: somatic mutations in chronic
lymphocytic leukemia (CLL) prognostic5. Identification of indels and their correction
(19) (option)
6. IMGT/Automat annotation (23, 24)
7. IMGT Colliers de Perles (29)
IMGT/HighV-QUEST (20, 25, 26) 1. Introduction of IMGT gaps User NGS long (e.g., from 454) nucleotide
sequences of V-DOMAIN (up to 500,000
sequences per runb)c (25, 26)
2. Identification of indels and their correction
(19) (by default)
3. Identification of the closest V, D, and J genes
and alleles
Applications: IG and TR immune repertoires and
clonotypes in NGS
4. IMGT/JunctionAnalysis results (21, 22)
5. Description of mutations and AA changes
6. IMGT/Automat annotation (23, 24)
7. Statistical analysis (25)
8. Characterization of the IMGT clonotypes (AA)
(26)
IG,TR, MH DOMAINAA SEQUENCEANALYSIS
IMGT/DomainGapAlign (12, 27, 28) 1. Introduction of IMGT gaps User AA sequences of V, C, and G-domains (one
to several sequences of same domain type)
(27, 28)
2. Identification of the closest genes and alleles
3. Delimitation of the domains
4. Description of AA changes Applications: IMGT antibody engineering and
humanization for V and C5. IMGT Colliers de Perles (67–70) with
highlighted AA changes (pink circles online)
IMGT® DATABASES
IMGT/3Dstructure-DB (11–13) 1. Identification of the closest genes and alleles 2,290 structure entries (1,987 IG, including 852
IG/Ag complexes, 151 TR, and 542 MH including
84 TR/pMH complexes)b
2. IMGT/DomainGapAlign results (12, 27, 28)
3. IMGT Collier de Perles (67–70) (on two layers
with hydrogen bonds for V and C or with pMH
contact sites for G)
Applications: identification of the paratope and
epitope in IG/AG and TR/pMH complexes and
pMH contacts4. Contact analysis between a pair of domains
or between a domain and a ligand
5. Renumbered IMGT files
6. IMGT numbering comparison
IMGT/2Dstructure-DB (13)* 1. Identification of the closest genes and alleles 512 AA sequence entriesb (of which 506 IG)*
2. IMGT/DomainGapAlign results (12, 27, 28) Applications: from gene to structures in the
absence of 3D3. IMGT Collier de Perles (67–70)
4. Renumbered IMGT files
An asterisk (*) indicates that parts of the protocol dealing with 3D structures (hydrogen bonds in IMGT Colliers de Perles on two layers, Contact analysis) are not
relevant, otherwise all other queries and results are similar to IMGT/3Dstructure-DB.
aV: V-domain (includes V-DOMAIN of IG and TR and V-LIKE-DOMAIN of IgSF other than IG and TR) (64). C: C-domain (includes C-DOMAIN of IG and TR and
C-LIKE-DOMAIN of IgSF other than IG and TR) (65). G: G-domain (G-DOMAIN of MH and G-LIKE-DOMAIN of MhSF other than MH) (8).
bIn November 2013.
cIn November 2013, more than 1.4 billions of sequences analyzed by IMGT/HighV-QUEST, by 702 users from 40 countries (43% users from USA, 38% from EU, 19%
from the remaining world).
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IMGT/HighV-QUEST
NGS IG and TR V-domain analysis
IMGT/HighV-QUEST (25), created in October 2010, is the high-
throughput version of IMGT/V-QUEST. It is so far the only online
tool available on the Web for the direct analysis of complete IG and
TR domain sequences from NGS. It analyzes sequences obtained
from the Roche 454 Life Sciences technology, without the need
of computational read assembly (25, 26). IMGT/HighV-QUEST
analyses up to 500,000 sequences per run in November 2013 (25,
26), with the same degree of resolution and high-quality results
as IMGT/V-QUEST (15–20). IMGT/HighV-QUEST represents a
major breakthrough for the analysis and the comparison of the
antigen receptor V-DOMAIN repertoires and immunoprofilings
of the adaptive immune response (25, 26).
The functionalities of IMGT/HighV-QUEST include: the intro-
duction of IMGT gaps, the identification of indels and their
correction (19) (by default), the identification of the closest V,
D, and J genes and alleles, the IMGT/JunctionAnalysis results,
the description of mutations and AA changes, the annotation
by IMGT/Automat, the NGS statistical analysis, and the char-
acterization of the IMGT clonotypes (AA) (25, 26) (Table 8).
IMGT/HighV-QUEST provides results in different categories “1
copy” and “More than 1” to avoid redundancy of the analy-
sis, “single allele” and “several alleles (or genes)” (with “single
allele” sequences being usually longer than “several alleles”) (25).
These categories have been fundamental in the characterization of
clonotypes for NGS (26).
As for the other IMGT® databases and tools, IMGT/HighV-
QUEST is freely available for academics. However, the
IMGT/HighV-QUEST Welcome page requires user identification
and provides, for new users, a link to register. User identification
has been set to avoid non-relevant use and overload of the server,
and to contact the user if needed. The user identification gives
access to the IMGT/HighV-QUEST Search page.
NGS IMGT® clonotype identification
IMGT clonotype (AA) identification: clonal diversity. In the
literature, clonotypes are defined differently, depending on the
experiment design (functional specificity) or available data. Thus,
a clonotype may denote either a complete antigen receptor (e.g.,
IgG1-kappa), or only one of the two chains of the receptor (e.g.,
H or L), or one domain (e.g., VH), or the CDR3 sequence of a
domain. Moreover the sequence can be at the AA or nucleotide
(nt) level, and this is rarely specified. Therefore, IMGT® goal
was first of all to define clonotypes and their properties, which
could be identified and characterized by IMGT/HighV-QUEST,
unambiguously (26).
In IMGT®, the clonotype, designated as “IMGT clonotype
(AA),” is defined by a unique V-(D)-J rearrangement (with IMGT
gene and allele names determined by IMGT/HighV-QUEST at
the nt level) and a unique CDR3-IMGT AA (in-frame) junction
sequence (26). For identifying “IMGT clonotypes (AA)” in a given
IMGT/HighV-QUEST dataset, the “1 copy” are filtered to select
for sequences with in-frame junction, conserved anchors 104 and
118 (“C” is 2nd-CYS 104, and “F” or “W” is the J-PHE or J-TRP
118) and for V and J functional or ORF, and “single allele” (for V
and J) (26).
By essence, an “IMGT clonotype (AA)” is “unique” for a given
dataset. For that reason, each “IMGT clonotype (AA),” in a given
dataset, has a unique set identifier (column“Exp. ID”) and, impor-
tantly, has a unique representative sequence (link in column
“Sequence ID”) selected by IMGT/HighV-QUEST among the “1
copy” “single allele” (for V and J), based on the highest percent of
identity of the V-REGION (“V%”) compared to that of the closest
germline, and/or on the sequence length (thus the most complete
V-REGION) (26).
Sequences assigned to IMGT clonotypes (AA): clonal expression.
Clonal expression is the number of sequences that can be assigned
to each IMGT clonotype (AA). In our procedure, the high-quality
and specific characterization of the “IMGT clonotype (AA)” (26)
remains unaltered whereas the total number of sequences assigned
to each given “IMGT clonotype (AA)” is calculated stepwise by
adding:
1. The number of the “1 copy” “single allele” sequences not
selected as representative. These sequences differ from the rep-
resentative sequence by a different (usually shorter) length,
and/or by sequencing errors in the V-REGION (lower “V%”
of identity) or in the J-REGION, and/or by nt differences
in the CDR3-IMGT. Sequences with nt differences in the
CDR3-IMGT are identified as “IMGT clonotypes (nt),” the
nt differences resulting from sequencing errors or, if this
can be proven experimentally, from molecular convergence.
For a given “IMGT clonotype (AA),” the number (nb) of
different CDR3-IMGT (nt) or “IMGT clonotypes (nt),” the
CDR3-IMGT sequence (nt) and the nb of different nt in the
CDR3-IMGT are reported in the results (26).
2. The number of the “1 copy” “several alleles (or genes)”
sequences that have the same V and J allele as the IMGT
clonotype (AA), among their IMGT/HighV-QUEST results.
3. The number of “More than 1” (including those of the IMGT
representative sequence) for each retained “1 copy” of steps 1
and 2 (25).
For the first time for NGS antigen receptor data analysis, the
IMGT® standardized approach allows a clear distinction and accu-
rate evaluation between the clonal diversity [nb of “IMGT clono-
types (AA)”], and the clonal expression [total nb of sequences
assigned, unambiguously, to a given “IMGT clonotype (AA)”]
(26). These assignments are clearly described and visualized in
detail so the user always has the means of checking clonotypes
individually. Indeed, the sequences of each “1 copy” assigned to
a given “IMGT clonotype (AA)” are available in “Sequences file”
(26). The user can easily perform an analysis of these sequences
online with IMGT/V-QUEST (up to 10 sequences, selecting “Syn-
thesis view display” and the option “Search for insertions and
deletions”) and/or with IMGT/JunctionAnalysis (up to 5,000 junc-
tion sequences), which provide a visual representation familiar to
the IMGT® users.
Clonal diversity is also visualized in the online results with his-
tograms, which represent the number of IMGT clonotypes (AA)
per V, D (for IGH, TRB or TRD), and J genes (in pink) (26).
Clonal expression is visualized with histograms, which represent
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the number of sequences assigned to IMGT clonotypes (AA) per
V (in green), D (in red), and J (in yellow) genes (26). Values are
normalized, respectively, for 10,000 IMGT clonotypes (AA) to rep-
resent IG diversity immunoprofiles per V, D (for IGH, TRB or
TRD), and J genes, and for 10,000 sequences assigned to IMGT
clonotypes (AA) to represent IG expression immunoprofiles per
V, D (for IGH, TRB or TRD), and J genes (26). These normalized
values allow comparative analysis studies performed with the same
IMGT/HighV-QUEST standards (26).
IMGT/DomainGapAlign
V, C, and G-domain analysis of IG, TR, and MH
IMGT/DomainGapAlign (12, 27, 28) is the IMGT® online tool
for the analysis of AA sequences and 2D structures of V and C-
domains (for IG, TR, and other IgSF) and of G-domains (for MH
and other MhSF) (Table 8). It analyzes domain AA sequences
by comparison with the IMGT domain reference directory sets
(translation of the germline V and J genes and of the C gene
domains for IG and TR, AA domain sequences of MH and con-
ventional genes). IMGT/DomainGapAlign functionalities include:
introduction of IMGT gaps in the user AA sequences, alignments,
and identification of the genes and alleles by comparison with the
closest domain(s), delimitation of the domain(s) (e.g., V, C, or G)
in the user sequence, description of the AA changes and IMGT
Collier de Perles.
IMGT domain reference directory
The IMGT domain reference directory is the IMGT reference
directory for V, C, and G-domains. Sequences are from the IMGT
Repertoire (1) and from IMGT/GENE-DB (10). Owing to the
particularities of the V-DOMAIN synthesis (2, 3), there is no V-
DOMAIN in the IMGT reference directory. Instead, the directory
comprises the translation of the IG and TR germline V and J genes
(V-REGION and J-REGION,respectively). The IMGT domain ref-
erence directory provides the IMGT® “gene” and “allele” names.
Data are comprehensive for human and mouse IG and TR whereas
for other species and other IgSF and MhSF they are added progres-
sively. The IMGT domain reference directory comprises domain
sequences of functional (F), ORF, and in-frame pseudogene (P)
genes. As IMGT® alleles are characterized at the nucleotide level,
identical sequences at the AA level may therefore correspond to
different alleles, in the IMGT domain reference directory. The
sequences can be displayed by querying IMGT/DomainDisplay
(see footnote text 1).
IMGT® DATABASES FOR IG, TR, ANDMH DOMAIN ANALYSIS
IMGT/3Dstructure-DB
IMGT/3Dstructure-DB card
IMGT/3Dstructure-DB (11–13), the IMGT® structure database,
provides IMGT® annotation and contact analysis of IG, TR, MH,
IgSf, and MhSF 3D structures, and paratope/epitope description
of IG/antigen and TR/pMH complexes (Table 8). There is one
“IMGT/3Dstructure-DB card” per IMGT/3Dstructure-DB entry
and this card provides access to all data related to that entry.
The “PDB code” (four letters and/or numbers, e.g., 1n0x) is used
as “IMGT entry ID” for the 3D structures obtained from the
Research Collaboratory for Structural Bioinformatics (RCSB) Pro-
tein Data Bank (PDB) (100). The IMGT/3Dstructure-DB card
provides eight search/display options: “Chain details,” “Contact
analysis,”“Paratope and epitope,”“3D visualization Jmol or Quick-
PDB,”“Renumbered IMGT files,”“IMGT numbering comparison,”
“References and links,” and “Printable card” (11–13).
IMGT chain and domain annotation
The “Chain details” section comprises information first on the
chain itself, then per domain (11–13). Chain and domain anno-
tation includes the IMGT gene and allele names (CLASSIFICA-
TION), region and domain delimitations (DESCRIPTION) and
domain AA positions according to the IMGT unique numbering
(NUMEROTATION) (8, 62–66). The closest IMGT® genes and
alleles (found expressed in each domain of a chain) are iden-
tified with the integrated IMGT/DomainGapAlign (12, 27, 28),
which aligns the AA sequences of the 3D structures with the IMGT
domain reference directory.
Contact analysis
“Contact analysis” gives access to a table with the different
“Domain pair contacts” of the 3D structure [this table is also
accessed from “Chain details” by clicking on “Domain contact
(overview)”]. “Domain pair contacts” refer to contacts between a
pair of domains or between a domain and a ligand. Clicking on
“DomPair” gives access to the contacts between AA for a given
“Domain pair contacts.” Contacts between VH and the Ligand
(antigen, Ag) and the V-KAPPA and the Ligand (Ag) of an IG/Ag
complex are shown in Figure 6. These contact analysis represen-
tations are important as they demonstrate that most contacts with
the ligand, if not all, involve the AA of the CDR-IMGT. They
definitively confirmed the CDR-IMGT delimitations as the official
reference standards (66, 70, 93).
In IMGT/3Dstructure-DB, all contacts are described as atom
pair contacts. Atom pair contacts are obtained by a local pro-
gram in which atoms are considered to be in contact when no
water molecule can take place between them (11, 12). Atom pair
contacts are provided by atom contact types (noncovalent, polar,
hydrogen bond, nonpolar, covalent, disulfide) and/or atom con-
tact categories [(BB) backbone/backbone, (SS) side chain/side
chain, (BS) backbone/side chain, (SB) side chain/backbone] (11,
12, 90, 91).
Clicking on “R@P” gives access to the IMGT identity card
of a given residue (usually an AA) at a given position or
Residue@Position. The IMGT R@P card can also be accessed from
the AA sequences of the IMGT/3Dstructure-DB card or from the
IMGT Colliers de Perles, by clicking on one AA. In an IMGT R@P
card, the Residue@Position is defined by the IMGT position num-
bering in a domain, or if not characterized, in the chain, the AA
name (three-letter and between parentheses one-letter abbrevia-
tions), the IMGT domain description and the IMGT chain ID,
e.g., “103 – TYR (Y) – VH – 1hzh_H” (11–13). The IMGT R@P
card includes (i) general information (PDB file numbering, IMGT
file numbering, residue full name and formula), (ii) structural
information “IMGT LocalStructure@Position” [secondary struc-
ture, Phi and Psi angles (in degrees) and accessible surface area
(ASA) (in square angstrom)] and (iii) detailed contact analysis
with AA of other domains (11–13).
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FIGURE 6 | IMGT/3Dstructure-DB Domain pair contacts betweenVH
andV-KAPPA and the ligand from an IG/Ag complex. The IG/Ag complex
structure is 1n0x from IMGT/3Dstructure-DB (http://www.imgt.org) (11–13).
The ligand is a synthetic peptide. (A) Domain pair contacts between VH and
the ligand. The Summary shows that there are a total of 106 atom pair
contacts (10 polar including 1 hydrogen bond and 96 non-polar) for 17 pair
contacts between the VH (1n0x_H) and the ligand (1n0x_P). Seven amino
acids (AA) of the VH interact with the ligand. The list of the pair contacts
show that three of them belong to the CDR2-IMGT (orange color online) and
two of them to the CDR3-IMGT (purple color online), and together
contribute to 81 atom pair contacts (including the hydrogen bond). The VH
binds the ligand primarily by the N64 of the CDR2-IMGT and the P112.3 and
Q112.2 of the CDR3-IMGT that are localized next to the top of the loops
(Figure 3). The only two positions of the FR-IMGT that have contacts with
the ligand are the anchors 55 and 66 of the CDR2-IMGT. In that structure,
there is no contact of the CDR1-IMGT. (B) Domain pair contacts between
V-KAPPA and the ligand. The Summary shows that there are a total of 195
atom pair contacts (32 polar including 3 hydrogen bonds and 163 non-polar)
for 24 pair contacts between the V-KAPPA (1n0x_L) and the ligand (1n0x_P).
Twelve AA of the VH interact with the ligand. The list of the pair contacts
show that seven of them belong to the CDR1-IMGT (blue color online) and
three of them to the CDR3-IMGT (greenblue color online) and together
contribute to 174 atom pair contacts (including the three hydrogen bonds).
The only two positions of the FR-IMGT that have contacts with the ligand
are the positions 1 and 2 of the strand A of the FR1-IMGT. In that structure,
there is no contact with the CDR2-IMGT.
Paratope and epitope
In an IG/Ag complex, the AA in contact at the interface between
the IG and the Ag constitute the paratope on the IG V-DOMAIN
surface,and the epitope on the Ag surface. Similarly, in an TR/pMH
complex, the AA in contact at the interface between the TR and
the pMH constitute the paratope on the TR V-DOMAIN surface,
and the epitope on the pMH surface. For IG/Ag and TR/pMH,
the paratope and epitope are displayed in Contact analysis, but
for each V-domain, separately. Clicking on the “Paratope and epi-
tope” tag (displayed in the IMGT/3Dstructure-DB card, only if
relevant), gives access to “IMGT paratope and epitope details”,
which are described in a standardized way. Each AA that belongs
to the paratope is defined by its position in a V-DOMAIN. Each AA
that belongs to the epitope in an IG/Ag complex is defined by its
position in the chain in the 3D structure or, if the antigen belongs
to an IgSF or MhSF protein and if the epitope is part of a character-
ized V, C, or G-domain, by its position in the domain according to
the IMGT unique numbering. The epitope in a TR/pMH complex
includes AA of the peptide and of the two G-DOMAIN helices.
Renumbered flat file and IMGT numbering comparison
“Renumbered IMGT file” allows to view (or download) an IMGT
coordinate file renumbered according to the IMGT unique num-
bering, and with added IMGT specific information on chains and
domains (added in the “REMARK 410” lines (blue online), and
identical to the “Chain details” annotation).
“IMGT numbering comparison” provides, per domain, the
IMGT DOMAIN numbering by comparison with the PDB num-
bering, and the residue (three-letter and one-letter names), which
allows standardized IMGT representations using generic tools
(Figures 3A and 4A).
IMGT/3Dstructure-DB associated tools
Tools associated to IMGT/3Dstructure-DB include IMGT/
StructuralQuery (11) and IMGT/DomainSuperimpose, avail-
able online. IMGT/StructuralQuery allows to retrieve the
IMGT/3Dstructure-DB entries, based on specific structural char-
acteristics of the intramolecular interactions: phi and psi angles,
ASA, type of atom contacts, distance in angstrom between
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AA, IMGT Residue@Position contacts and, for V-DOMAIN,
CDR-IMGT length or pattern (11). IMGT/DomainSuperimpose
allows to superimpose the 3D structures of two domains from
IMGT/3Dstructure-DB.
IMGT/2Dstructure-DB
IMGT/2Dstructure-DB was created as an extension of
IMGT/3Dstructure-DB (11–13) to describe and analyze AA
sequences of chains and domains for which no 3D struc-
tures were available (Table 8). IMGT/2Dstructure-DB uses the
IMGT/3Dstructure-DB informatics frame and interface, which
allow one to analyze, manage, and query IG, TR, and MH, as well
as other IgSF and MhSF and engineered proteins (FPIA, CPCA),
as polymeric receptors made of several chains, in contrast to the
IMGT/LIGM-DB sequence database that analyzes and manages
sequences individually (9). The AA sequences are analyzed with
the IMGT® criteria of standardized identification (59), description
(60), nomenclature (61), and numerotation (8, 62–66).
The current IMGT/2Dstructure-DB entries include AA
sequences of antibodies from Kabat (94) (those for which there
were no available nucleotide sequences), and AA sequences of
mAb and FPIA from the WHO–INN Programme (14, 50, 51).
Queries can be made on an individual entry, using the Entry
ID or the Molecule name. The same query interface is used
for IMGT/2Dstructure-DB and IMGT/3Dstructure-DB. Thus a
“trastuzumab” query in “Molecule name” allows to retrieve three
results: two INN (“trastuzumab” and “trastuzumab emtansine”)
from IMGT/2Dstructure-DB, and one 3D structure (“1nz8”) from
IMGT/3Dstructure-DB.
The IMGT/2Dstructure-DB cards provide standardized IMGT
information on chains and domains and IMGT Colliers de Perles
on one or two layers, identical to that provided for the sequence
analysis in IMGT/3Dstructure-DB, however the information on
experimental structural data (hydrogen bonds in IMGT Collier de
Perles on two layers, Contact analysis) is only available in the cor-
responding IMGT/3Dstructure-DB cards, if the antibodies have
been crystallized.
IMGT® V AND C-DOMAIN FOR ANTIBODY HUMANIZATION
AND ENGINEERING
CDR-IMGT DELIMITATION FOR GRAFTING
The objective of antibody humanization is to graft at the DNA
level the CDR of an antibody V-domain, from mouse (or other
species) and of a given specificity, onto a human V-domain frame-
work, thus preserving the specificity of the original (murine
or other species) antibody while decreasing its immunogenicity
(101). IMGT/DomainGapAlign (12,27,28) is the reference tool for
antibody humanization design based on CDR grafting. Indeed, it
precisely defines the CDR-IMGT to be grafted and helps selecting
the most appropriate human FR-IMGT by providing the align-
ment of the AA sequences between the mouse (or other species)
and the closest human V-DOMAIN.
Analyses performed on humanized therapeutic antibodies
underline the importance of a correct delimitation of the CDR and
FR. As an example, two AA changes were required in the first ver-
sion of the humanized VH of alemtuzumab, in order to restore the
specificity and affinity of the original rat antibody. The positions
of these AA changes (S28> F and S35> F) are now known to
be located in the CDR1-IMGT and should have been directly
grafted, but at the time of this mAb humanization they were con-
sidered as belonging to the FR according to the Kabat numbering
(94). In contrast, positions 66–74 were, at the same time, consid-
ered as belonging to the CDR according to the Kabat numbering,
whereas they clearly belong to the FR2-IMGT and the correspond-
ing sequence should have been “human” instead of being grafted
from the “rat” sequence (IMGT®, see footnote text 1, The IMGT
Biotechnology page>Antibody humanization>Alemtuzumab).
IGHG1 ALLELES AND G1m ALLOTYPES
Allotypes are polymorphic markers of an IG subclass that corre-
spond to AA changes and are detected serologically by antibody
reagents (76). In therapeutic antibodies (human, humanized, or
chimeric) (14), allotypes may represent potential immunogenic
residues (75), as demonstrated by the presence of antibodies in
individuals immunized against these allotypes (76). The allotypes
of the human heavy gamma chains of the IgG are designated as
Gm (for gamma marker).
The allotypes G1m, G2m, and G3m are carried by the constant
region of the gamma1, gamma2, and gamma3 chains, encoded
by the IGHG1, IGHG2, and IGHG3 genes, respectively (76). The
gamma1 chains may express four G1m alleles (combinations of
G1m allotypes): G1m3, G1m3,1, G1m17,1, and G1m17,1,2 (and
in Negroid populations two additional G1m alleles, Gm17,1,28
and Gm17,1,27,28) (76) (Table 9). The C-region of the G1m3,1,
G1m17,1, and G1m17,1,2 chains differ from that of the G1m3
chains by two, three, and four AA, respectively (76). The cor-
respondence between the G1m alleles and IGHG1 alleles is
shown in Table 9. Thus, IGHG1*01 and IGHG1*02 are G1m17,1,
IGHG1*03 is G1m3, IGHG1*04 is G1m17,1,2 and IGHG1*05 is
G1m3,1.
In the IGHG1 CH1, the lysine at position 120 (K120) in strand
G corresponds to the G1m17 allotype (76) (Figure 4D). The
isoleucine I103 (strand F) is specific of the gamma1 chain isotype.
If an arginine is expressed at position 120 (R120), the simultaneous
presence of R120 and I103 corresponds to the expression of the
G1m3 allotype (76). For the gamma3 and gamma4 isotypes (which
also have R120 but T in 103), R120 only corresponds to the expres-
sion of the nG1m17 isoallotype (an isoallotype or nGm is detected
by antibody reagents that identify this marker as an allotype in one
IgG subclass and as an isotype for other subclasses) (76).
In the IGHG1 CH3, the aspartate D12 and leucine L14 (strand
A) correspond to G1m1, whereas glutamate E12 and methion-
ine M14 correspond to the nG1m1 isoallotype (76) (Table 9).
A glycine at position 110 corresponds to G1m2, whereas an ala-
nine does not correspond to any allotype (G1m2-negative chain)
(Table 9). Therapeutic antibodies are most frequently of the IgG1
isotype, and to avoid a potential immunogenicity, the constant
region of the gamma1 chains are often engineered to replace the
G1m3 allotype by the less immunogenic G1m17 (CH1 R120>K)
(G1m17 is more extensively found in different populations) (76).
CONCLUSION
IMGT-ONTOLOGY and the IMGT® information system, which
are at the origin of immunoinformatics, have provided the
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Table 9 | Correspondence between the IGHG1 alleles and G1m alleles.
IGHG1 alleles G1m allelesa IMGT amino acid (AA) positionsb Populations (76)
Allotypes Isoallotypesc CH1 CH3
103 120 12 14 110
G1m3d G1m17/nG1m1 G1m1/nG1m1 G1m2/-
IGHG1*01e G1m17,1 I K D L A Caucasoid Negroid
IGHG1*02e Mongoloid
IGHG1*03 G1m3 nG1m1, nG1m17 I R E M A Caucasoid
IGHG1*04f G1m17,1,2 I K D L G Caucasoid
Mongoloid
IGHG1*05f G1m3,1 nG1m17 I R D L A Mongoloid
aIn Negroid populations, the G1m17,1 allele frequently includes G1m27 and G1m28, leading to two additional G1m alleles, G1m17,1,27 and G1m17,1,27,28 (76).
bAA corresponding to G1m allotypes are shown in bold.
cThe nG1m1 and nG1m17 isoallotypes present on the Gm1-negative and Gm17-negative gamma1 chains (and on other gamma chains) are shown in italics.
dThe presence of R120 is detected by anti-nG1m17 antibodies whereas the simultaneous presence of I103 and R120 in the gamma1 chains is detected by anti-Gm3
antibodies (76).
eThe IGHG1*01 and IGHG1*02 alleles only differ at the nucleotide level (codon 85.1 in CH2).
fIGHG1*04 and IGHG1*05 AA are expected (76) but not yet sequenced at the nucleotide level and therefore the IGHG1*04 and IGHG1*05 alleles are not shown in
IMGT Repertoire, Alignments of alleles: Homo sapiens IGHG1 (http:// www.imgt.org).
concepts, the knowledge environment, and the informatics frame
for a standardized and integrated analysis of IG, TR, and MH,
extended to other IgSF (102–106) and MhSF (96, 97), from gene
to structure and function (32–47). IG and TR repertoire analysis,
antibody humanization, IG and TR engineering for immunother-
apy, paratope/epitope characterization represent major current
fields of immunoinformatics at the forefront of basic, clinical, and
pharmaceutical research owing to major methodological advances
and medical implications.
The IMGT® standards are used in clinical applications. Thus,
IMGT/V-QUEST is frequently used by clinicians for the analy-
sis of IG somatic hypermutations in leukemia, lymphoma, and
myeloma, and more particularly in chronic lymphocytic leukemia
(CLL) (18, 72–74) in which the percentage of mutations of the
rearranged IGHV gene in the VH of the leukemic clone has a
prognostic value for the patients. For this evaluation, IMGT/V-
QUEST is the standard recommended by the European Research
Initiative on CLL (ERIC) for comparative analysis between labo-
ratories (72). The sequences of the V–(D)–J junctions determined
by IMGT/JunctionAnalysis (21, 22) are also used in the char-
acterization of stereotypic patterns in CLL (73, 74) and for the
synthesis of probes specific of the junction for the detection and
follow-up of minimal residual diseases (MRD) in leukemias and
lymphomas. A new era is opening in hemato-oncology with the
use of NGS for analysis of the clonality and MRD identification,
making IMGT® standards use more needed as ever. More generally,
the IMGT/HighV-QUEST web portal is a paradigm for identifica-
tion of IMGT clonotype diversity and expression in NGS immune
repertoire analysis of the adaptive immune response in infec-
tious diseases, in vaccination, and for next-generation repertoire
immunoprofiling (26).
The therapeutic monoclonal antibody engineering field repre-
sents the most promising potential in medicine. A standardized
analysis of IG genomic and expressed sequences, structures, and
interactions is crucial for a better molecular understanding and
comparison of the mAb specificity, affinity, half-life, Fc effector
properties, and potential immunogenicity. IMGT-ONTOLOGY
concepts have become a necessity for IG loci description of newly
sequenced genomes, antibody structure/function characteriza-
tion, antibody engineering [single chain Fragment variable (scFv),
phage displays, combinatorial libraries] and antibody humaniza-
tion (chimeric, humanized, and human antibodies) (35, 42, 44, 46,
75–77, 82). IMGT® standardization allows repertoire analysis and
antibody humanization studies to move to novel high-throughput
methodologies with the same high-quality criteria. The CDR-
IMGT lengths are now required for mAb INN applications and
are included in the WHO–INN definitions (51), bringing a new
level of standardized information in the comparative analysis of
therapeutic antibodies.
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